News

Our latest community news, ALLG News Edition 9, is now available! Download a copy to read about the importance of Blood Cancer Awareness Month, which occurs annually every September, key important dates within this month and how ALLG is driving research to deliver new innovative leading-edge clinical trials to improve the survival and quality of life of patients with blood cancer.

You can also read about two significant ALLG international collaborative trials have been recognised globally:

ALLG HD10 trial – with the German Hodgkin Study Group (GHSG) and recently published in The Lancet, demonstrated superior outcomes for survival, quality of life and fertility and have now set the benchmark on how this type of Hodgkin lymphoma will be treated globally.

ALLG AMLM26 INTERCEPT clinical trial – investigating innovative new treatments for patients with acute myeloid leukaemia (AML), recently received FDA approval to open in the United States at the prestigious MD Anderson Cancer Center.

ALLG’s innovative research has had a significant impact over the last 50 years, driving improvements in treatments for patients worldwide and accelerating research to potentially find a cure for blood cancers.

Read more about ALLG’s blood cancer research by downloading our ALLG News, Edition 9. 

 

ALLG News Edition 9 Insights

In ALLG News Edition 9, hear from blood cancer patients who have experienced ALLG trials and what survivorship means to them. Find out how ALLG is at the forefront of emerging therapies, driving research to bring breakthrough treatments to patients across Australia and New Zealand through our expert member haematologists, to achieve our mission of Better treatments…Better lives.

Learn about the teams behind the trials, including how their work ensures ALLG can continue to investigate new treatments to continuously improve and evolve new treatment regimens for patients with blood cancer.

Download ALLG News Edition 9 and stay up to date with innovative blood cancer trials and treatments by subscribing to ALLG’s Community Newsletters.

 

ALLG’s Impact – Blood Cancer Treatments

ALLG is Australasia’s only not-for-profit, collaborative blood cancer clinical trial group. Our 1,400+ leading haematologists, scientists, and blood cancer researcher members are dedicated to accelerating blood cancer treatments and better patient outcomes, while we aim for cure.

Visit ALLG to learn more about our organisation and the many ways you can help support our research.